Living Factories: Why Scaling Fungal Drug Production Is More About Physics Than Biology

From Natural Compound to Industrial Challenge

Psilocybin has traveled an unusual path — from a compound found in Psilocybe mushrooms, long studied for its psychoactive properties, to a serious candidate in clinical psychiatry. Research into its potential for treating depression, anxiety, and treatment-resistant conditions has generated enough evidence that regulatory agencies in several countries are now actively reviewing it. With that clinical momentum comes a practical question: where does the material come from, and how do you make enough of it?

Chemical synthesis is one answer. It works, but it is complex, requires multiple reaction steps, and generates significant waste along the way. As interest in psilocybin-based therapies grows, researchers have turned to biological production — specifically, engineering fungi to manufacture the compound through fermentation. The appeal is clear: a living organism that produces the target molecule continuously, running on relatively simple inputs.

But biology, it turns out, is only part of the problem.

Engineering Fungi Is Only the First Step

In controlled laboratory studies, researchers engineered Aspergillus nidulans — a well-characterized filamentous fungus used widely in research — to carry out psilocybin biosynthesis. The approach involved introducing a sequence of biosynthetic genes that redirect the organism’s existing metabolic machinery toward producing the target compound. At the molecular level, the system works. The fungus takes in simple precursors and converts them, step by step, into psilocybin through a chain of enzymatic reactions.

Laboratory results were promising. But a laboratory flask and an industrial bioreactor are different environments in almost every way that matters for production — and what works at small scale does not automatically survive the transition to large scale.

When Growth Becomes a Physical Barrier

The problem begins with something that looks like success: the fungus grows.

Unlike bacteria or yeast, which grow as individual suspended cells, filamentous fungi grow as branching networks — mycelium. In liquid culture, these networks expand and intertwine, forming dense, three-dimensional structures that are very different from a simple cell suspension. As biomass increases, the culture changes character. It thickens. It becomes harder to stir. The distribution of oxygen and nutrients, which was relatively uniform in a small flask, becomes increasingly uneven.

The most critical consequence is oxygen. Even when oxygen is being actively pumped into the system, it cannot easily reach organisms buried inside dense fungal structures. In the zones where oxygen runs short, metabolic activity slows. Compound production drops. The organism is still alive and still capable of producing psilocybin — but the physical environment is preventing it from doing so.

Oxygen as the True Bottleneck

Oxygen is not a minor input for fungal metabolism. For the synthesis of complex secondary compounds like psilocybin, it is central. Multiple steps in the biosynthetic pathway depend on it, and when it runs short, the entire chain slows.

In dense fungal cultures, oxygen transfer is constrained from multiple directions simultaneously. The medium becomes more viscous as biomass increases, slowing the movement of dissolved gases. The architecture of the mycelium creates barriers that oxygen must diffuse through rather than flow around. And the simple act of supplying more oxygen externally does not resolve the problem — the limitation is delivery, not supply.

This is the distinction that makes scaling fungal systems fundamentally harder than scaling bacterial ones. You can increase the oxygen going in. Getting it where it needs to go is a different challenge entirely.

The Trade-Off: Mixing vs Structural Integrity

The standard engineering response to poor mass transfer is increased mixing. Stir faster, turn over the culture more aggressively, and oxygen and nutrients distribute more evenly. For bacteria or yeast, this works. For filamentous fungi, it creates a different problem.

Mycelial networks are physically delicate. Aggressive agitation generates shear forces — mechanical stress that tears at the fungal structure. Damaged mycelium produces less. Push mixing too hard, and productivity falls not because of oxygen limitation but because the organism is being broken apart by the solution to the oxygen problem.

This leaves a narrow operating window: too little mixing, and oxygen does not reach where it is needed; too much mixing, and the fungus is physically damaged. Finding and maintaining conditions within that window, across a vessel large enough for industrial production, is one of the central engineering challenges in fungal bioprocessing.

Pressure as an Engineering Solution

One approach that avoids the mixing dilemma entirely is to change the physics of oxygen transfer rather than forcing more mechanical action.

Increasing system pressure raises the solubility of oxygen in the liquid medium. More oxygen dissolves at the same partial pressure, and more dissolved oxygen means better availability throughout the culture — without increasing agitation. The mycelium experiences less mechanical stress while gaining access to more of the oxygen it needs to sustain biosynthesis.

This is a conceptual shift as much as a technical one. Instead of trying to push oxygen through a resistant medium by force, the approach changes the conditions under which oxygen moves — making diffusion more effective without increasing the forces that damage the organism.

Nutrients and Interdependent Constraints

Oxygen is not the only variable. Nitrogen — a key component of the amino acids and enzymes involved in biosynthesis — depletes as the culture grows. When nitrogen runs short early, the enzymatic machinery needed to produce psilocybin becomes limited. Adding more nitrogen extends productive operation and improves yield.

But increasing nutrients also increases the organism’s metabolic activity, which increases its demand for oxygen. The system is not a collection of independent variables — it is a set of interacting constraints. Adjusting one changes the demands on the others. Optimizing fungal production at scale means managing all of them simultaneously, with changes in any one parameter rippling through the rest of the system.

From Constraint to Capability

Through systematic optimization of pressure, nutrient supply, and mixing conditions, researchers achieved a psilocybin production level of 542 mg/L within 68 hours — a meaningful result for a compound that has historically been difficult to produce at scale through biological means.

The number matters. But what it demonstrates matters more: the constraints that limit fungal production at scale are engineering problems, not biological ones. The organism is capable. The question is whether the environment can be designed to let that capability operate.

Beyond One Compound: A Broader Shift in Biotechnology

Aspergillus nidulans and psilocybin are a specific case. The principles they illustrate are not.

Filamentous fungi are used across biotechnology and pharmaceuticals — producing enzymes, antibiotics, organic acids, and a range of bioactive molecules with medical and industrial applications. In every case, the same physical constraints apply: oxygen transfer, viscosity, shear sensitivity, nutrient dynamics. The insights from psilocybin fermentation carry directly into those systems.

The broader implication is a reorientation in how fungal production is approached. Engineering the organism — giving it the genetic capacity to produce something — is necessary but not sufficient. Engineering the environment in which the organism operates is equally important, and in scaling scenarios, often more limiting.

When Systems Define Biology

There is a tendency to frame biotechnology challenges as fundamentally biological — as problems of genetics, metabolism, and cellular function. Fungal biomanufacturing complicates that framing in a useful way.

The organism’s genetic capacity sets what is possible. But the physical environment — oxygen availability, fluid dynamics, mechanical stress, nutrient distribution — determines what actually happens. Fungi do not fail to produce because something is wrong with their biology. They fail when the environment prevents the biology from operating as it should.

In that sense, the most important frontier in fungal biotechnology is not the genome. It is the bioreactor.

FAQ

Why is fungal production harder than bacterial production? Filamentous fungi form dense mycelial structures that limit oxygen transfer and complicate mixing in ways that suspended bacterial cultures do not.

What limits psilocybin production in bioreactors? Primarily oxygen availability and nutrient balance — both shaped by the physical properties of the culture as biomass increases.

Why can’t mixing simply be increased? Higher mixing generates shear stress that physically damages mycelial networks, reducing productivity rather than improving it.

How does pressure improve production? Increased pressure raises oxygen solubility in the liquid medium, improving oxygen availability throughout the culture without requiring more aggressive agitation.

Can this approach apply to other compounds? Yes. The same physical constraints — oxygen limitation, viscosity, shear sensitivity — affect most filamentous fungal production systems across biotechnology and pharmaceuticals.

References

• Biotechnology & Bioengineering — Psilocybin Production in Aspergillus nidulans: https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/bit.70137